NASDAQ:ZLABZai Lab Stock Price, Forecast & News

$68.36

+0.92 (+1.36 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$67.44

Now: $68.36▼

$69.98

50-Day Range

$51.36

MA: $63.93▼

$73.37

52-Week Range

$25.51

Now: $68.36▼

$76.39

Volume472,185 shs

Average Volume457,875 shs

Market Capitalization$3.97 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.06

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.

Beat the Market (BTM) Rank^™

1.5 Analyst's Opinion

Consensus Rating
Zai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $57.31, Zai Lab has a potential downside of 16.2% from its current price of $68.36.
Amount of Analyst Coverage
Zai Lab has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Zai Lab has received 180 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zai Lab has received 210 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zai Lab has received 53.85% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote “Outperform” if you believe ZLAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zai Lab does not currently pay a dividend.
Dividend Growth
Zai Lab does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zai Lab insiders have not sold or bought any company stock.
Percentage Held by Institutions
78.29% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Zai Lab are expected to grow in the coming year, from ($3.46) to ($3.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zai Lab is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zai Lab is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zai Lab has a P/B Ratio of 13.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.09 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZLAB

Previous Symbol

CUSIPN/A

CIK1704292

Webwww.zailaboratory.com

Phone86-21-6163-2588

Debt

Debt-to-Equity RatioN/A

Current Ratio6.27

Quick Ratio6.14

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.98 million

Price / Sales306.01

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.07 per share

Price / Book13.48

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees309

Outstanding Shares58,105,000

Market Cap$3.97 billion

Next Earnings DateN/A

OptionableOptionable

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

How has Zai Lab's stock been impacted by COVID-19 (Coronavirus)?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZLAB shares have increased by 36.4% and is now trading at $68.36. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zai Lab?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zai Lab.

How were Zai Lab's earnings last quarter?

Zai Lab Ltd (NASDAQ:ZLAB) released its quarterly earnings results on Thursday, March, 19th. The company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.05. The company earned $4.65 million during the quarter. View Zai Lab's earnings history.

What price target have analysts set for ZLAB?

7 analysts have issued 1-year price targets for Zai Lab's shares. Their forecasts range from $36.54 to $84.00. On average, they anticipate Zai Lab's stock price to reach $57.31 in the next year. This suggests that the stock has a possible downside of 16.2%. View analysts' price targets for Zai Lab.

Has Zai Lab been receiving favorable news coverage?

Media headlines about ZLAB stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zai Lab earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutZai Lab.

Are investors shorting Zai Lab?

Zai Lab saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,920,000 shares, a drop of 11.9% from the April 15th total of 2,180,000 shares. Based on an average trading volume of 507,200 shares, the short-interest ratio is presently 3.8 days. Currently, 3.5% of the company's stock are sold short. View Zai Lab's Current Options Chain.

Who are some of Zai Lab's key competitors?

Some companies that are related to Zai Lab include Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD) and Ionis Pharmaceuticals (IONS). View all competitors.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), InVitae (NVTA), Baozun (BZUN), Fulgent Genetics (FLGT), Intellia Therapeutics (NTLA), Beigene (BGNE), Marvell Technology Group (MRVL) and Niu Technologies (NIU).

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:

Dr. Ying Du, Founder, Chairman & CEO (Age 53)
Mr. Tao Fu, Pres, COO & Director (Age 47)
Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital World Investors (10.12%), Baillie Gifford & Co. (5.36%), Wellington Management Group LLP (4.73%), BlackRock Inc. (3.56%), Federated Hermes Inc. (3.42%) and Segantii Capital Management Ltd (3.13%).

Which institutional investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Segantii Capital Management Ltd, Orbimed Advisors LLC, Wellington Management Group LLP, AXA, Greenwoods Asset Management Ltd, Wells Fargo & Company MN, Morgan Stanley, and Invesco Ltd..

Which institutional investors are buying Zai Lab stock?

ZLAB stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, BlackRock Inc., State Street Corp, Federated Hermes Inc., Vivo Capital LLC, Assenagon Asset Management S.A., Casdin Capital LLC, and Legal & General Group Plc.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $68.36.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $3.97 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Zai Lab employs 309 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff